The Phosphate-Specific Transport System Gene pstA1 Contributes to Rifampin Tolerance in Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Tuberculosis (TB) causes significant global mortality, necessitating prolonged antibiotic treatment.
• Antibiotic tolerance allows Mycobacterium tuberculosis (Mtb) to survive treatment without mutations, contributing to lengthy therapy and drug resistance.
• The PstA1 transporter is implicated in Mtb virulence and survival under nutrient limitation.

Purpose of the Study:

• To investigate the role of PstA1 in Mtb's tolerance to rifampin.
• To evaluate PstA1 as a potential drug target for adjunctive TB therapy.

Main Methods:

• Forward genetic screen to identify rifampin tolerance genes.
• Construction and analysis of a pstA1 deletion mutant (ΔpstA1).
• Time-kill assays to assess rifampin susceptibility.
• Differential gene expression analysis.

Main Results:

• ΔpstA1 mutants showed increased susceptibility to rifampin, with faster bacterial killing.
• PstA1 is essential for Mtb survival in low-phosphate conditions and within macrophages.
• Transcriptional analysis revealed significant reprogramming in ΔpstA1 mutants, affecting metabolic and repair pathways.
• Rifampin MIC was unaffected in ΔpstA1, indicating tolerance, not resistance.

Conclusions:

• PstA1 is a key factor in Mtb's tolerance to rifampin.
• Inhibiting PstA1 could enhance antibiotic efficacy and shorten TB treatment duration.
• Targeting PstA1 represents a promising strategy for adjunctive therapy against tuberculosis.